Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Science, 2019 The dope on l-dopa metabolism The efficacy of l-dopa treatment for Parkinson's disease is hugely variable between individuals, depending on the composition of their microbiota.
Vayu Maini Rekdal +4 more
semanticscholar +1 more source
Nature Communications, 2019 Human gut microbiota senses its environment and responds by releasing metabolites, some of which are key regulators of human health and disease. In this study, we characterize gut-associated bacteria in their ability to decarboxylate levodopa to dopamine
Bailey D'Antonio, Laura Yamagata
openalex +3 more sources
Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment [PDF]
, 1997 Neuropsychiatric side effects often complicate anti-Parkinsonian therapy and pose a significant problem in the optimal management of idiopathic Parkinson's disease.
Abbott, R.J. +6 more
core +2 more sources
Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology. [PDF]
, 2014 Maladaptive plasticity can be defined as behavioral loss or even development of disease symptoms resulting from aberrant plasticity changes in the human brain.
Ahmed +58 more
core +2 more sources
Sonolysis of levodopa and paracetamol in aqueous solutions. [PDF]
, 2009 Pharmaceutical products are often present in wastewater treatment effluents, rivers, lakes and, more rarely, in groundwater. The advanced oxidation methods, like ultrasound, find a promising future in the area of wastewater treatment.
Delmas, Henri +4 more
core +1 more source
Adrenal pheochromocytoma incidentally discovered in a patient with parkinsonism [PDF]
, 2015 To evaluate the diagnostic route of pheochromocytoma (PHEO) in a patient under dopaminergic treatment. A 70-year-old man with Parkinsonism and under treatment with levodopa and carbidopa came to our observation for evaluation of arterial hypertension and
Claudio Letizia +7 more
core +1 more source
ACS Sensors, 2019 Levodopa is the most effective medication for treating Parkinson's disease (PD). However, because dose optimization is currently based on patients' report of symptoms, which are difficult for patients to describe, the management of PD is challenging.
K. Y. Goud +6 more
semanticscholar +1 more source
New advances in amblyopia therapy I: Binocular therapies and pharmacologic augmentation [PDF]
, 2018 Amblyopia therapy options have traditionally been limited to penalisation of the non-amblyopic eye with either patching or pharmaceutical penalisation. Solid evidence, mostly from the Pediatric Eye Disease Investigator Group, has validated both number of
Culican, Susan M, Kraus, Courtney L
core +2 more sources
Elevated Levels of Methylmalonate and Homocysteine in Parkinson's Disease, Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis [PDF]
, 2010 Background/Aims: Increasing evidence suggests that elevated levels of homocysteine (Hcy) and methylmalonate (MMA) may be involved in the pathogenesis of neurodegenerative diseases. Methods: The urine levels of MMA and serum levels of Hcy as well as folic
Bötzel, Kai +4 more
core +1 more source
Randomized Delayed‐Start Trial of Levodopa in Parkinson's Disease
New England Journal of Medicine, 2019 BACKGROUND Levodopa is the main treatment for symptoms of Parkinson's disease. Determining whether levodopa also has a disease‐modifying effect could provide guidance as to when in the course of the disease the treatment with this drug should be ...
C. V. Verschuur +13 more
semanticscholar +1 more source